New homogeneous high-throughput assays for inhibitors of β-catenin/Tcf protein-protein interactions

Min Zhang1, Zheng Huang, Binxun Yu

  • 1Department of Chemistry, Center for Cell and Genome Science, University of Utah, Salt Lake City, UT 84112-0850, USA.

Analytical Biochemistry
|February 29, 2012
PubMed

Insights

Researchers developed two new high-throughput assays to identify inhibitors of the beta-catenin/T-cell factor (Tcf) complex, crucial in cancer and fibrosis. These assays enable rapid screening for potential therapeutic strategies targeting these protein-protein interactions.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Drug Discovery

Background:

  • The canonical Wnt/β-catenin signaling pathway is regulated by the transcriptional activator β-catenin.
  • Aberrant β-catenin/T-cell factor (Tcf) complex formation is implicated in various cancers and organ fibroses.
  • Targeting β-catenin/Tcf protein-protein interactions offers a promising therapeutic avenue.

Purpose of the Study:

  • To establish robust, homogeneous high-throughput assays for studying β-catenin/Tcf interactions.
  • To enable the quantification of inhibitory potency against the β-catenin/Tcf complex.
  • To facilitate the rapid identification of novel inhibitors for therapeutic development.

Main Methods:

  • Development and validation of AlphaScreen assay.
  • Development and validation of fluorescence polarization assay.
  • Utilizing these assays to study β-catenin/Tcf protein-protein interactions and inhibitor screening.

Main Results:

  • Two new high-throughput assays (AlphaScreen and fluorescence polarization) were successfully established.
  • These assays accurately reproduce native β-catenin/Tcf interactions.
  • The assays demonstrated complementary capabilities in quantifying inhibitory potency.

Conclusions:

  • The developed high-throughput assays are effective tools for studying β-catenin/Tcf interactions.
  • These assays facilitate the rapid screening and identification of potential inhibitors.
  • This work supports the development of new therapeutic strategies for diseases driven by aberrant Wnt/β-catenin signaling.

Related Concept Videos